Strongbridge Dublin Ltd. Patent Application Ruling: Federal Circuit Affirms-in-Part in Pharmaceutical Compositions Case
What would you like to explore next?
Choose your path based on your interest in patent prosecution:
📋 Appeal Summary
| Case Name | In re: Strongbridge Dublin Ltd. |
| Case Number | 23-2302 (Fed. Cir.) |
| Court | Federal Circuit, Appeal from USPTO PTAB |
| Duration | Aug 2023 – Mar 2025 567 days |
| Outcome | Affirmed-in-Part, Vacated-in-Part, Remanded |
| Patent Application at Issue | |
| Subject Matter | Pharmaceutical Compositions & Methods of Use |
Appeal Overview
The Parties
👨⚖️ Appellant
Specialty pharmaceutical company focused on rare endocrine diseases, challenging USPTO rejections of its patent application.
🏛️ Appellee
Represented by Derrick Brent, Acting Under Secretary of Commerce for IP, defending the USPTO’s patentability determination.
Patent Application at Issue
This appeal involved U.S. Patent Application No. US17/151405 (published as US20210290542A1), covering specific pharmaceutical compositions and methods of use.
- • US17/151405 — Pharmaceutical compositions
- • US20210290542A1 — Methods of use for these compositions
Developing new drug formulations?
Check if your pharmaceutical compositions might encounter similar patentability challenges.
The Verdict & Legal Analysis
Outcome
The Federal Circuit issued a significant affirmed-in-part, vacated-in-part, and remanded ruling, indicating a mixed outcome for Strongbridge. No monetary damages were at issue, as this was a patentability proceeding. The vacated claims now return to the USPTO for further examination.
Verdict Cause & Legal Issues
The core verdict cause was patentability/invalidity-cancellation, with common grounds like Obviousness (§ 103) and Enablement/Written Description (§ 112) likely at play. The vacatur and remand provide a critical opportunity for Strongbridge to secure allowance on certain claims, subject to addressing the Federal Circuit’s guidance. The partial dismissal of appeal grounds highlights the importance of precise procedural management during prosecution.
Drafting pharma patent claims?
Leverage AI to draft robust claims for your pharmaceutical compositions.
Power Your Patent Strategy with Eureka IP
From novelty searches to patent drafting, Eureka’s AI-powered tools help you navigate the patent landscape with confidence.
🔬 Patentability & Risk Assessment
This case highlights critical IP risks in pharmaceutical composition development. Choose your next step:
📋 Understand this Case’s Impact
Learn about the specific prosecution and appellate implications from this ruling.
- View related pharmaceutical composition patents
- See key prior art in this tech space
- Understand claim construction trends in pharma
🔍 Check My Compositions’ Patentability
Run a comprehensive patentability assessment for your own drug formulations.
- Input your composition details or therapeutic uses
- AI identifies potentially blocking prior art
- Get actionable patentability assessment
High Scrutiny Area
Pharmaceutical composition claims often face rigorous review.
Complex Prior Art
Many related patents in this therapeutic space.
Strategic Remand Opportunity
Vacated claims offer a path to allowance.
✅ Key Takeaways
For Patent Prosecutors
Federal Circuit split outcomes demand granular claim-by-claim prosecution records for successful appeals.
Search related appellate decisions →Partial dismissals highlight procedural preservation failures — build appellate records at every prosecution stage.
Explore appeal best practices →For IP Portfolio Strategists & R&D Teams
The affirmed-in-part outcome means Strongbridge’s patent position is weakened but not eliminated; assess continuation strategy for remanded claims.
Start Patentability analysis for my product →Pharmaceutical composition IP remains highly contestable; FTO analyses must account for pending applications and appellate outcomes.
Try AI patent drafting for pharma →Ready to Strengthen Your Patent Strategy?
Join thousands of IP professionals using Eureka to conduct prior art searches, draft patents, and analyze competitive landscapes.